Article Abstract

Targeting the epigenome in malignant pleural mesothelioma

Authors: Kaitlin C. McLoughlin, Andrew S. Kaufman, David S. Schrump

Abstract

Malignant pleural mesotheliomas (MPM) are notoriously refractory to conventional treatment modalities. Recent insights regarding epigenetic alterations in MPM provide the preclinical rationale for the evaluation of novel combinatorial regimens targeting the epigenome in these neoplasms.

Refbacks

  • There are currently no refbacks.